About Lilly Ventures
Lilly Ventures is a venture capital firm founded in 2001. It is primarily based out of Indianapolis, United States. As of Feb 2024, Lilly Ventures has invested in 39 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series D round of BioAge Labs Overall, Lilly Ventures portfolio has seen 8 IPOs and 19 acquisitions including key companies like Coherus Biosciences, Sutro Biopharma and Protagonist Therapeutics. A lot of funds co-invest with Lilly Ventures, with names like SR One sharing a substantial percentage of its portfolio. Lilly Ventures has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series C & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Lilly Ventures' List of Top Investments
Lilly Ventures has a portfolio of 39 companies. Their most notable investments are in Lysosomal Therapeutics and Numerate.Their portfolio spans across United States and Israel. They have invested in Life Sciences, High Tech, Enterprise Applications and 5 other sectors, across stages such as Series A, Series C and 4 more. Here is the list of top investments by Lilly Ventures:Key facts about Coherus Biosciences
- Founded Year: 2010
- Location: Redwood City (United States)
- Annual Revenue: $267M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $144M
- Employee Count: 285 as on Apr 11, 2025
- Investors: RA Capital Management, F-Prime Capital and 13 Others
- Latest Funding Round: Post IPO, Apr 14, 2020, $*****
- Highlight: Public
Developer of antibody-based therapeutics for cancer therapy. The company uses cell-free protein synthesis platform XpressCF technology led to the discovery of STRO-001 and STRO-002, for B-cell malignancies, ovarian and endometrial cancers.
Key facts about Sutro Biopharma
- Founded Year: 2003
- Location: United States
- Annual Revenue: $559K as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $175M
- Employee Count: 223 as on Mar 31, 2026
- Investors: Amgen Business Development, Citadel and 17 Others
- Latest Funding Round: Series E, Jul 26, 2018, $*****
- Highlight: Public
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.
Key facts about Nimbus Therapeutics
- Founded Year: 2009
- Location: Cambridge (United States)
- Stage: Series F
- Total Funding till date: $637M
- Employee Count: 101 as on Mar 31, 2026
- Investors: BVF Partners, Access Industries and 20 Others
- Latest Funding Round: Series F, Sep 06, 2023, $*****
- Highlight: Editors' Pick
Developer of oral peptide therapeutics for gastrointestinal diseases. It offers orally stable peptide therapeutics for drugs against inflammatory bowel diseases (IBD), irritable bowel syndrome disease-related targets, and gastrointestinal diseases and disorders. It offers IL-6, a peptide antagonist as an anti-inflammatory agent; and a novel hepcidin peptide mimetic for the treatment of iron overload related disorders. Its pipeline includes PTG-100, an a4ß7 integrin-specific oral peptide antagonist for the treatment of IBDs; and IL-23, a receptor oral peptide antagonist for the treatment of IBDs.
Key facts about Protagonist Therapeutics
- Founded Year: 2001
- Location: Milpitas (United States)
- Annual Revenue: $434M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $67M
- Employee Count: 112 as on Dec 31, 2023
- Investors: Aisling Capital, RA Capital Management and 12 Others
- Latest Funding Round: Post IPO, Aug 09, 2023, $*****
- Highlight: Public
5. Kymeratx
Developer of small molecule protein degraders for multiple disorders. It offers small molecules to target IRAK4, IRAKIMiD, and STAT3, and has the potential to treat immune-inflammatory diseases, hematologic malignancies, and solid tumors. It offers targeted protein degradation platforms and functions on the principle of the ubiquitin-proteasome system, which plays an integral role in regulating cellular processes.
Key facts about Kymeratx
- Founded Year: 2016
- Location: Cambridge (United States)
- Annual Revenue: $41.5M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $197M
- Employee Count: 289 as on Mar 31, 2026
- Investors: HTIF, BVF Partners and 22 Others
- Latest Funding Round: Post IPO, Aug 19, 2022, $*****
- Highlight: Public
Lilly Ventures' Year-on-Year Investment Trends
Lilly Ventures has invested in 39 companies over the last 25 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in BioAge Labs and most recent follow-on round was in Kymeratx.Lilly Ventures' Investments by Stage
Lilly Ventures has made 12 investments in Series A stage with an average round size of $19.7M, 11 investments in Series C stage with an average round size of $23.8M and 10 investments in Series B stage with an average round size of $22M.Stage of entry | No. of Investments |
|---|---|
Series A | 12 |
Series C | 11 |
Series B | 10 |
Series D | 4 |
PE | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Lilly Ventures' Investments by Sector
Lilly Ventures has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Healthcare, HealthTech and High Tech. Notably, it has invested in 31 Tech companies, 24 Enterprise (B2B) companies, 9 Software companies and at least 5 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 30 |
Enterprise Applications | 6 |
Healthcare | 6 |
HealthTech | 4 |
High Tech | 4 |
Others | 8 |
Note: We have considered here, only first round of investments
Lilly Ventures' Investments by Geography
Lilly Ventures has made most investments in United States (38), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 38 |
Israel | 1 |
Note: We have considered here, only first round of investments
Lilly Ventures' recent investments
Lilly Ventures has not made any investment in 2026 so far.Here are the most recent investments by Lilly Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 13, 2024 | United States | Series D | 4575 | [+11] | |
Nov 13, 2018 | United States | Series B | 6961 | [+8] | |
Jul 26, 2018 | United States | Series E | 7466 | [+11] | |
Oct 30, 2017 | United States | Series A | 7080 | [+1] | |
Jan 13, 2017 | United States | Series A | 1167 | [+6] |
IPOs and Publicly Listed companies in Lilly Ventures' Portfolio
8 of Lilly Ventures' portfolio companies have become public. BioAge Labs got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2024 at marketcap of $615M and Kymeratx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $863M.Here are Lilly Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 26, 2024 | Feb 13, 2024 | Series D | 4629 | |
Aug 21, 2020 | Oct 30, 2017 | Series A | 6153 | |
Sep 27, 2018 | Nov 05, 2010 | Series C | 8196 | |
Jun 30, 2017 | Jun 08, 2009 | Series D | 1771 | |
Aug 11, 2016 | Sep 19, 2006 | Series A | 8809 |
Acquired companies in Lilly Ventures' Portfolio
19 companies from Lilly Ventures' portfolio have been acquired. The most recent acquisition were Surface Oncology in Jun 2023 by Coherus Biosciences.Here are Lilly Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 16, 2023 | Jan 08, 2015 | Series A | 5025 | |
Sep 01, 2022 | Dec 01, 2009 | Series B | 4343 | |
Jul 10, 2020 | Feb 01, 2006 | Series A | 3458 | |
Aug 12, 2019 | Jan 12, 2017 | Series A | 8987 | |
Jun 01, 2019 | Jun 04, 2014 | Series C | 3322 |
Team profile of Lilly Ventures
Lilly Ventures has a team of 1 member. Lilly Ventures' team does not sit on the board of any company as of now.Co-investors of Lilly Ventures
Over the past 25 years, 262 investors have co-invested in Lilly Ventures's portfolio companies. This includes funds and angels.
- Invested before Lilly Ventures: HHS, Alta Partners and 52 others have invested in rounds before Lilly Ventures. There are 3 companies where HHS has invested before Lilly Ventures and 2 companies where Alta Partners has invested before Lilly Ventures.
- Top Co-investors of Lilly Ventures: 102 investors entered a company along with Lilly Ventures. These include investors like SR One (5 companies).
- Invested after Lilly Ventures: A total of 106 investors have invested in Lilly Ventures's portfolio after their investments. Top Investors include RA Capital Management (4 companies), Celgene (3 companies) and HHS (3 companies).
Recent News related to Lilly Ventures
•
BioAge secures $170m for obesity therapeutics developmentPharmaceutical Technology•Feb 14, 2024•BioAge Labs, Sofinnova Investments, RA Capital Management, Longitude Capital and 15 others
•
Life Sciences and Healthcare Industry Leaders Invest in Tact.ai to Deliver Next Generation Customer EngagementPR Newswire•Sep 21, 2021•Tact, Novartis, Lilly Ventures, McKesson Ventures and 2 others
•
Vertex pays Kymera $70M upfront to discover protein degradation drugsFierce Biotech•May 15, 2019•Kymeratx, 6 Dimensions Capital, Bessemer Venture Partners, Pfizer and 9 others
•
•
Sutro Biopharma Announces $85.4 Million Series E RoundPR Newswire•Jul 26, 2018•Sutro Biopharma, Samsara BioCapital, Citadel, Alta Partners and 10 others
•
Kymera Therapeutics announces $30 mln series A financing roundReuters•Oct 30, 2017•Kymeratx, Amgen, Atlas Biomed, Lilly and 3 others
•
Cavion Raises $26.1M Series ACitybizlist•Jan 08, 2017•Cavion, Nobilis Health, Suzlon, Realogy and 4 others
•
Innocrin Pharmaceuticals, Inc. Raises $28 Million in Series D Financing | Business WireBusiness Wire•Apr 14, 2015•Innocrin, Eshelman Ventures, Novartis Venture Fund, Lilly Ventures and 2 others
•
Aeglea Biotherapeutics Raises $44 Million in Series B Financing | Business WireBusiness Wire•Mar 23, 2015•Aeglea, Lilly Ventures, Novartis Venture Fund, UT Horizon Fund and 6 others
•
Pfizer joins a powerhouse syndicate backing $43M round for Nimbus | FierceBiotechFierce Biotech•Mar 18, 2015•Nimbus Therapeutics, Lightstone Ventures, Pfizer, Atlas Venture and 2 others
